Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab

The Common Terminology Criteria for Adverse Events (CTCAE) were developed to document the adverse effects of chemotherapy but are now also used to document immune-related adverse events (irAE). Characterization of irAE by the CTCAE has implications for determining dose-limiting toxicity (DLT) and, c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute Jg. 109; H. 4
Hauptverfasser: Friedman, Claire F, Clark, Varina, Raikhel, Andrew V, Barz, Tim, Shoushtari, Alexander N, Momtaz, Parisa, Callahan, Margaret K, Wolchok, Jedd D, Chapman, Paul B, Hellmann, Matthew D, Postow, Michael A
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.04.2017
Schlagworte:
Amylases - blood
Antibodies, Monoclonal - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Female
Humans
Ipilimumab
Lipase - blood
Male
Melanoma - drug therapy
Pancreatitis - blood
Pancreatitis - chemically induced
Retrospective Studies
ISSN:1460-2105
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The Common Terminology Criteria for Adverse Events (CTCAE) were developed to document the adverse effects of chemotherapy but are now also used to document immune-related adverse events (irAE). Characterization of irAE by the CTCAE has implications for determining dose-limiting toxicity (DLT) and, consequently, the recommended phase II dose (RP2D) of investigational agents. In the phase I trial of nivolumab + ipilimumab, an asymptomatic increase in lipase was the primary DLT that informed the RP2D. We performed a retrospective study of 119 patients with melanoma who were treated at Memorial Sloan Kettering Cancer Center with the combination of nivolumab + ipilimumab to investigate the relationship between asymptomatic grade 3 or higher increases in amylase and/or lipase and pancreatitis, a known irAE. Of the 119 patients, there were only two cases of pancreatitis, representing 20% of patients with grade 3 or higher amylase, 6.3% of patients with grade 3 or higher lipase, and 20% of patients with grade 3 or higher elevations of both enzymes. The application of the CTCAE, especially in grading independent lab values, should be considered carefully in clinical trials of novel immunotherapeutic agents.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1460-2105
DOI:10.1093/jnci/djw260